- Investors may be wondering whether Madrigal Pharmaceuticals, at around US$445 a share, still offers value or if most of the opportunity has already been priced in.
- The stock has recent returns of 0.4% over 7 days, 2.3% over 30 days, a 25.1% decline year to date, and a 29.6% return over 1 year. This mixed performance can leave investors unsure how to read the risk and reward trade off.
- These moves sit against a backdrop where Madrigal Pharmaceuticals continues to attract attention in the biotech space and remains a focus for investors assessing long term potential. Recent headlines have kept the company on the radar of both growth oriented and risk cautious investors, adding context to the share price swings.
- The company currently has a valuation score of 4/6. The sections that follow will compare different valuation methods, then finish with a broader framework that can help you think about value beyond any single model.
Approach 1: Madrigal Pharmaceuticals Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and discounting them back to the present using a required return.
For Madrigal Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is a loss of about $192.4 million. Analyst and extrapolated projections move from an estimated $151.4 million free cash flow in 2026 to $2,294.5 million in 2035, with intermediate steps such as $520.4 million in 2027 and $1,715.6 million in 2030. All figures are in $ and are treated in millions rather than billions.
After discounting these projected cash flows, the model arrives at an estimated intrinsic value of about $1,807.61 per share. Compared with a current share price around $445, this indicates the stock screens as significantly undervalued using this particular DCF setup.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Madrigal Pharmaceuticals is undervalued by 75.4%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.
Approach 2: Madrigal Pharmaceuticals Price vs Sales
For companies where earnings are not the main focus yet, the P/S ratio is a useful way to think about value because it anchors the share price to the revenue investors are paying for each dollar of sales.
What counts as a normal P/S ratio depends a lot on how quickly revenue is expected to change and how much risk investors see in the business. Higher expected growth or lower perceived risk can support a higher multiple, while slower growth or higher risk usually points to a lower one.
Madrigal Pharmaceuticals currently trades on a P/S of 10.65x. This is close to the wider Biotechs industry average of 10.30x and sits below the peer group average of 24.13x. Simply Wall St’s Fair Ratio framework estimates a P/S of 17.14x for Madrigal, based on factors such as growth expectations, industry, profit margins, market cap and risk profile.
This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts the target multiple to the company’s own characteristics rather than relying only on broad group averages. With the current P/S of 10.65x below the Fair Ratio of 17.14x, Madrigal screens as undervalued on this measure.
Result: UNDERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Madrigal Pharmaceuticals Narrative
Earlier it was mentioned that there is an even better way to think about valuation, so Narratives are introduced, which are short, clear stories that link your view of Madrigal Pharmaceuticals to specific forecasts for revenue, earnings and margins, and then to a fair value that can be compared with today’s price.
On Simply Wall St’s Community page, Narratives let you set out this story in an accessible format. This allows you to see how a particular forecast, discount rate and multiple feed into a fair value and helps you decide whether the current price looks high or low against your own assumptions.
Because Narratives update when new information such as news, licensing deals or earnings arrives, you can keep the story and the numbers aligned instead of working off stale models or old price targets.
For Madrigal, for example, one Narrative might lean toward the more cautious fair value implied by a bearish target of US$266, while another could reflect the more optimistic view behind a US$567 target. Seeing both side by side makes it easier for you to decide which story, and which fair value, fits what you believe is realistic.
Do you think there's more to the story for Madrigal Pharmaceuticals? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com